YOLFTbeta
Valion Bio Inc

Valion Bio Inc

VBIO · NASDAQ · Healthcare / Biotechnology

0.5293USD+0.02 (+4.05%)

Price History

Full chart

Market Stats

Previous Close0.5087
Open0.50
Day Range0.4774 – 0.5499
52-Week Range2.05 – 78.75
Volume98.58K
Market Cap2.69M
P/E (TTM)0.00
Forward P/E0.00
EPS-184.45
Dividend Yield0.00%
Beta1.79
50-Day Avg4.98
200-Day Avg20.51

About

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Lisa G. Wolf
  • Employees52
  • Headquarters1305 E. Houston Street, San Antonio, TX, United States, 78205, USA
  • Websitehttps://valionbio.com

Leadership

  • Ms. Lisa G. WolfPresident, CFO & COO · b. 1962
  • Ms. Melinda LackeyGeneral Counsel & Senior Vice President of Legal Affairs · b. 1977

Financials

Income Statement

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue----245.68K248.35K163.36K102.42K420.00K860.00K1.26M1.84M1.18M0382.00K
Growth (%)-----+1.09%-34.22%-37.30%+310.08%+104.76%+46.16%+46.38%-36.09%-100.00%-
Cost of Revenue----121.34K149.48K108.26K77.94K713.00K1.09M1.30M1.54M889.00K352.00K350.00K
Gross Profit----124.34K98.87K55.10K24.48K-293.00K-233.00K-46.00K299.00K287.00K-352.00K32.00K
Gross Margin----50.61%39.81%33.73%23.90%-69.76%-27.09%-3.66%16.25%24.40%-8.38%
Operating Expense----3.93M2.84M3.53M4.42M3.35M3.09M5.59M10.40M8.53M4.06M7.93M
Operating Income-26.45M-30.00K-2.44M-3.60M-3.81M-2.74M-3.47M-4.40M-3.64M-3.32M-5.63M-10.10M-8.24M-4.42M-7.90M
Operating Margin-----1548.83%-1103.99%-2125.09%-4292.86%-867.38%-386.16%-448.13%-548.80%-701.11%--2067.54%
EBITDA-28.29M-35.33K-2.31M-3.75M-4.04M-140.97K-5.22M-4.31M-3.64M-3.31M-5.61M-9.92M-8.06M-4.06M-7.84M
EBITDA Margin-----1645.35%-56.76%-3194.40%-4207.19%-866.43%-385.23%-446.22%-539.35%-685.63%--2052.88%
Net Income-28.29M-40.00K-2.74M-4.15M-4.05M-141.33K-5.22M-4.31M-4.15M-3.64M-8.49M-10.10M-8.24M-5.66M-8.88M
Net Income Margin-----1647.82%-56.91%-3195.02%-4207.19%-987.62%-423.14%-675.74%-548.70%-701.02%--2324.08%
R&D--250.00K580.00K1.13M613.12K893.96K1.90M986.00K768.00K870.00K1.73M1.66M1.31M3.13M
R&D as % of Total Revenue----460.49%246.88%547.23%1852.98%234.76%89.30%69.21%94.02%140.73%-819.63%
Interest Expense2.26K4.67K425.37K404.32K6.07K3631.01K-443.00K423.00K1.82M--0146.00K
Interest Expense % of Total Revenue----2.47%0.15%0.62%-105.48%49.19%145.03%---38.22%

Balance Sheet

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.72M10.00K540.00K1.42M462.30K134.80K1.18M675.79K3.02M1.53M15.04M5.88M5.16M2.81M31.61M
Total Liabilities51.70M100.00K1.11M1.53M1.54M652.96K800.65K353.52K653.00K2.71M1.76M2.25M1.58M272.00K14.81M
Total Equity-49.99K-85.26K-568.11K-110.38K-1.08M-518.16K374.37K322.27K2.37M-1.18M13.27M3.63M3.58M2.54M16.80M
Cash1.72M10.00K390.00K1.40M389.73K95.43K1.15M656.29K2.31M1.04M12.97M3.52M3.40M2.00M12.64M
Total Debt41.80M80.00K580.00K------1.47M708.00K530.00K369.00K-6.45M
Net Debt40.08M70.00K190.00K-1.40M-389.73K-95.43K-1.15M-656.29K-2.31M425.00K-12.27M-2.99M-3.03M-2.00M-6.19M

Cash Flow

Currency: USD2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-31.54K-26.12K-1.65M-2.13M-2.50M-1.69M-1.38M-2.89M-3.67M-3.03M-5.61M-8.92M-8.51M-5.72M-7.00M
Investing Cash Flow---1.00K-10.51K----31.00K---11.00K-118.00K--705.00K
Financing Cash Flow16.80K35.00K1.51M3.14M1.48M1.39M2.44M2.39M5.55M1.76M17.54M-528.00K8.51M4.33M18.35M
Capital Expenditure0038.09K0000031.00K0011.00K118.00K038.00K
Free Cash Flow-31.54K-26.12K-1.65M-2.13M-2.50M-1.69M-1.38M-2.89M-3.70M-3.03M-5.61M-8.93M-8.63M-5.72M-7.04M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.84%100.00%100.00%100.12%101.39%100.00%100.54%

Earnings

Report DateDec 31, 2021Jun 1, 2022Aug 15, 2022Nov 14, 2022Mar 31, 2023May 16, 2023Aug 14, 2023Nov 14, 2023Mar 26, 2024May 16, 2024Aug 15, 2024Nov 15, 2024Mar 24, 2025May 15, 2025Aug 15, 2025Nov 17, 2025May 15, 2026Aug 14, 2026Nov 13, 2026
EPS Estimate---408.00-544.00-527.00-4675.00-136.00-119.00-----------
EPS Actual-16290.91-9799.04-544.00-459.00-391.00-4675.00-119.00-25.16-650.22-428.84-134.19-98.23-66.30-2.52-54.78-49.14-53.77-2.17-
Surprise---33.33%15.63%25.81%0.00%12.50%78.86%-----------
Timing--After-hoursPre-marketPre-market-After-hoursAfter-hours-----------

Key Statistics & Ratios

Market Cap2.69M
Enterprise Value17.75M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.52
Price / Book0.52
EPS-184.45
Book Value1.02
Revenue (TTM)-86.00K
Gross Profit (TTM)-54.00K
EBITDA-16.54M
Profit Margin0.00%
Operating Margin19652.33%
Return on Equity-459.52%
Return on Assets-57.13%
Shares Outstanding887.59K
Shares Float879.58K
Beta1.79
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Ownership Breakdown

Institutions
12.42%
Insiders
0.63%
Retail / Other
86.95%

Top Institutional Holders

  • Geode Capital Management, LLC
    87.82K2.80%
  • Sanctuary Advisors, LLC
    61.20K1.95%
  • Marex Group Ltd
    59.26K1.89%
  • HRT FINANCIAL LLC
    42.42K1.35%
  • XTX Topco Ltd
    10.51K0.33%
  • UBS Group AG
    2.37K0.08%
  • Tower Research Capital LLC
    5840.02%
  • SBI Securities Co Ltd
    160.00%
  • Caitong International Asset Management Co., Limited.
    10.00%
  • Susquehanna International Group, LLP
    00.00%
  • Citigroup Inc
    00.00%
  • Bank of America Corp
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    18.90K0.09%

Stock Splits

  • Aug 31, 20261:25
  • Mar 7, 20251:17
  • Aug 23, 20231:100